- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Differentiated Thyroid Cancer with a Focus on Adverse Event Management
January 21, 2021
Steven Sherman, MD, FACE, provides insight on the treatment of radioactive iodine-refractory differentiated thyroid cancer and the management of adverse events.